Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/106786
Title: | Immunological function restoration with Lopinavir/ritonavir vs Efavirenz containing regimens in HIV infected patients: a randomized clinical trial |
Author: | Torres, Berta Rallón, Norma Loncá, Montserrat Díaz Lorca, Maria Alba Alós i Hernández, Llúcia Martínez Chamorro, Esteban José Cruceta, Anna Arnaiz Gargallo, Juan Alberto Leal, Lorna Lucero, Constanza León García, Agathe Sánchez, Marcelo Negredo, Eugènia Clotet, Bonaventura, 1953- Gatell, José M. Benito, José M. García Alcaide, Felipe |
Keywords: | VIH (Virus) Sistema immunològic Antiretrovirals HIV (Viruses) Immune system Antiretroviral agents |
Issue Date: | 2-May-2014 |
Publisher: | Mary Ann Liebert |
Abstract: | CD4+ count increase has been reported to be different with lopinavir/r (LPV/r) and efavirenz (EFV)-containing regimens. The different effect of these two regimens on other immune function parameters and the relationship with the gain of CD4+ count have not been assessed in a randomized clinical trial. Fifty antiretroviral treatment (cART) naïve HIV-infected individuals were randomized to receive LPV/r or EFV both with tenofovir/emtricitabine for 48 weeks. A substudy of immunological function restoration was performed in 22 patients (LPV/r n=10 and EFV n=12). Activation, thymic function, apoptosis, senescence, exhaustion, Treg cells, interleukin (IL)-7-receptor/IL-7 system, thymic volume, and lymphoid tissue fibrosis were evaluated at baseline and at week 48. Both groups experienced a CD4+ count increase that was higher in the EFV group (ΔCD4+ 88 vs. 315 cells/μl LPV/r vs. EFV, respectively, p<0.001). Despite this difference in CD4+ gain, the change in other immune function parameters was similar in both treatment groups. Most of parameters evaluated tended to normalize after 48 weeks of cART. A significant decrease in levels of activation, senescence, exhaustion, and apoptosis on CD4+ and CD8+ T cells (p<0.001 for all) and a significant increase in markers of thymic function, IL-7 receptor, and in the levels of central memory CD4+ T cells and naive subsets of CD8+ T cells (p<0.001 for all) with respect to baseline values were observed without any difference between groups. These data indicate that the differences in CD4+ gain with different cART regimens are not immunologically meaningful and might explain the similar clinical efficacy of these regimens. |
Note: | Reproducció del document publicat a: https://doi.org/10.1089/aid.2013.0185 |
It is part of: | Aids Research and Human Retroviruses, 2014, vol. 30, num. 5, p. 425-433 |
URI: | http://hdl.handle.net/2445/106786 |
Related resource: | https://doi.org/10.1089/aid.2013.0185 |
ISSN: | 0889-2229 |
Appears in Collections: | Articles publicats en revistes (Medicina) Articles publicats en revistes (Fonaments Clínics) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
635577.pdf | 463.91 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.